Loading clinical trials...
Loading clinical trials...
A Multi Center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC 67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-resistant Tuberculosis
Conditions
Interventions
Delamanid
Optimized Background Regimen (OBR)
+1 more
Locations
17
United States
University of Texas Health Center at Tyler / Heartland National TB Center / Texas Center for Infectious Disease
San Antonio, Texas, United States
Beijing Chest Hospital
Beijing, China
Shanghai Pulmonary Hospital
Shanghai, China
Abbassia Chest Hospital
Cairo, Egypt
North Estonian Medical Centre Foundation
Tallinn, Estonia
Tartu University Lung Hospital
Tartu, Estonia
Start Date
May 8, 2008
Primary Completion Date
June 11, 2010
Completion Date
June 11, 2010
Last Updated
December 1, 2021
NCT05756582
NCT05539014
NCT07077213
NCT04734652
NCT04865536
NCT05640648
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions